Gastrointestinal Drugs

Gastrointestinal Drugs Market Outlook

The global gastrointestinal drugs market is projected to reach approximately USD 71 billion by 2035, growing at a compound annual growth rate (CAGR) of around 5.4% during the forecast period of 2025 to 2035. The increasing prevalence of gastrointestinal disorders such as acid-related diseases, inflammatory bowel diseases, and irritable bowel syndrome is driving this growth. Moreover, the rising aging population and changes in dietary habits contribute to the escalation of gastrointestinal issues, thereby amplifying the demand for effective gastrointestinal drugs. Additionally, advancements in pharmaceutical research and development, along with the introduction of novel therapies, are expected to further enhance market growth. The ongoing focus on preventive care and the integration of digital health technologies are also pivotal factors in shaping the future of the gastrointestinal drugs market.

Growth Factor of the Market

One of the primary growth factors of the gastrointestinal drugs market is the rising incidence of gastrointestinal diseases across global demographics. Conditions such as gastroesophageal reflux disease (GERD), ulcers, and chronic constipation are becoming increasingly common due to lifestyle changes, including poor dietary habits, sedentary lifestyles, and increased stress. Furthermore, the awareness surrounding gut health has led to a higher consumption of medication aimed at managing these conditions. The growing acceptance of over-the-counter (OTC) medications in treating mild to moderate gastrointestinal issues has also significantly contributed to market growth. Additionally, the expansion of online pharmacies has made it easier for consumers to access these medications, further driving sales. The continuous investment in research and development by pharmaceutical companies to innovate and create more effective drugs tailored for specific gastrointestinal issues is another crucial factor fueling the market's expansion.

Key Highlights of the Market

• Growth projected at a CAGR of 5.4% from 2025 to 2035.
• Increasing prevalence of gastrointestinal diseases driving demand.
• Expansion of online pharmacy distribution channels.
• Heightened awareness of gut health influencing consumer choices.
• Innovations in drug development boosting market potential.

By Product Type

Antacids:

Antacids are a crucial segment of the gastrointestinal drugs market, used primarily to neutralize excess stomach acid and provide rapid relief from heartburn and indigestion. With the increasing incidence of acid-related disorders such as gastroesophageal reflux disease (GERD), the demand for antacids has soared. These medications, which include active ingredients like magnesium hydroxide, aluminum hydroxide, and calcium carbonate, are commonly available over the counter, making them accessible to a broad consumer base. As consumer awareness about self-medication rises, the popularity of antacids continues to grow, contributing significantly to market revenues.

Proton Pump Inhibitors:

Proton pump inhibitors (PPIs) represent another vital category within the gastrointestinal drugs market. These medications work by inhibiting the proton pump in the stomach lining, thereby reducing the production of gastric acid. PPIs have become a go-to treatment for chronic conditions such as GERD and peptic ulcers, owing to their efficacy and longer-lasting effects compared to traditional antacids. The increasing prescription rates for PPIs, alongside the growing trend of preventative healthcare, have significantly propelled their market demand. Additionally, the development of new formulations and combination therapies is expected to enhance their therapeutic appeal further.

H2 Receptor Antagonists:

H2 receptor antagonists, which function by blocking histamine receptors in the stomach to reduce acid secretion, have also seen a steady growth within the gastrointestinal drugs market. These medications are particularly effective for treating conditions like peptic ulcers and GERD. As healthcare practitioners increasingly recognize the importance of targeted therapies, the demand for H2 receptor antagonists remains robust. The availability of both prescription and OTC formulations has further bolstered their market presence. However, competition with PPIs, which are more effective for chronic acid suppression, may influence the sales dynamics of H2 receptor antagonists in the future.

Prokinetics:

Prokinetics are designed to enhance gastrointestinal motility and facilitate the movement of food through the digestive system. These medications are particularly beneficial for patients suffering from conditions like gastroparesis and functional dyspepsia. As awareness of gut health and motility disorders increases, the demand for prokinetic agents has grown significantly. Innovations in this segment, including the development of newer formulations with fewer side effects, are likely to attract consumer attention and boost market growth. The integration of prokinetics into broader treatment regimens for gastrointestinal disorders highlights their growing significance in the market.

Antiemetics:

Antiemetics are essential drugs used to prevent and treat nausea and vomiting associated with various conditions, ranging from chemotherapy-induced nausea to motion sickness. The rising prevalence of nausea-related disorders, coupled with an increase in cancer treatments, has propelled the demand for antiemetic medications. With advancements in formulation techniques, including the development of long-acting injectable options, the antiemetic segment has witnessed substantial growth. The increasing number of patients undergoing chemotherapy and the need for effective management of side effects have further reinforced the market's potential for antiemetics.

By Application

Acid-related Diseases:

The segment of acid-related diseases represents a significant portion of the gastrointestinal drugs market, encompassing conditions such as GERD, peptic ulcers, and esophagitis. The growing population experiencing these ailments due to factors such as dietary habits, obesity, and increased caffeine consumption has driven a surge in demand for relevant medications. Medications like PPIs and H2 receptor antagonists are commonly prescribed for these conditions, contributing to the market's growth. The increasing awareness around the management of acid-related diseases is expected to create further opportunities for pharmaceutical companies to innovate and expand their product offerings.

Inflammatory Bowel Disease:

Inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, represents another critical application area within the gastrointestinal drugs market. The rising prevalence of IBD, particularly in developed regions, has fueled demand for targeted therapies, including corticosteroids, immunosuppressants, and biologics. Pharmaceutical advancements in the development of more effective and personalized treatments have enhanced patient quality of life and are expected to drive market expansion. Additionally, the increasing focus on research pertaining to the underlying causes of IBD is likely to yield novel treatment options, further boosting market dynamics.

Irritable Bowel Syndrome:

Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder characterized by symptoms such as abdominal pain, bloating, and altered bowel habits. As awareness of IBS continues to grow, patients are seeking effective management options, driving demand for medications tailored for this condition. The development of specific treatments targeting IBS symptoms, including antispasmodics and newer agents like guanylate cyclase-C agonists, has opened up significant opportunities in the market. The increased emphasis on gut health and digestive wellness contributes to the robust growth potential for medications aimed at managing IBS.

Constipation:

Constipation, a common gastrointestinal complaint, has seen a growing focus within the gastrointestinal drugs market. The demand for laxatives and other therapeutics aimed at relieving constipation is rising due to factors such as an aging population, sedentary lifestyles, and the widespread use of medications that may contribute to constipation. Pharmacological options vary from osmotic laxatives to stimulant laxatives, catering to different patient needs. As healthcare providers emphasize the importance of digestive health, the market opportunities for constipation treatments are anticipated to expand, providing a promising avenue for growth.

Others:

The "Others" category encapsulates a range of gastrointestinal conditions not specifically covered in the aforementioned segments. This includes various functional gastrointestinal disorders, such as gastroparesis and dyspepsia, which require targeted therapeutic interventions. The diversity of this category underscores the breadth of the gastrointestinal drugs market, as innovative treatment options are developed to address lesser-known conditions. As research efforts continue to unveil the complexities of gastrointestinal health, the market potential within this segment is likely to grow, with new therapies emerging to meet patient needs.

By Distribution Channel

Hospital Pharmacies:

Hospital pharmacies play a crucial role in the distribution of gastrointestinal drugs, particularly for patients requiring specialized care and prescription medications. With healthcare facilities increasingly focusing on integrated care models, hospital pharmacies are becoming essential in managing complex gastrointestinal diseases. The presence of trained pharmacists ensures that patients receive tailored medication and counseling regarding their treatment plans. The growing number of hospital admissions related to gastrointestinal issues further drives the demand for medications dispensed through hospital pharmacies, making this channel vital in the market's overall landscape.

Retail Pharmacies:

Retail pharmacies are a primary distribution channel for gastrointestinal drugs, offering a wide range of over-the-counter and prescription medications. The convenience of accessing these pharmacies, along with the ability to easily consult with pharmacists, fosters consumer trust and encourages medication use. The rising trend towards self-medication for mild gastrointestinal disorders has significantly bolstered sales through retail pharmacies. As the focus on health and wellness continues to grow, retail pharmacies are likely to enhance their product offerings in gastrointestinal health, providing even more options for consumers seeking effective treatments.

Online Pharmacies:

Online pharmacies have emerged as a significant distribution channel for gastrointestinal drugs, particularly in the wake of the digital transformation in healthcare. The convenience of purchasing medications online, coupled with the ability to compare prices and read reviews, appeals to a broad consumer base. Additionally, the rising trend of telemedicine has facilitated the growth of online pharmacies, allowing patients to obtain prescriptions and medications from the comfort of their homes. As e-commerce continues to expand, online pharmacies are expected to play an increasingly important role in the gastrointestinal drugs market, providing accessibility and affordability to consumers.

By Ingredient Type

Antacids:

Antacids serve as a foundational ingredient type in the gastrointestinal drugs market, renowned for their ability to neutralize stomach acid and provide quick relief from heartburn and indigestion. Common active ingredients such as magnesium hydroxide and calcium carbonate are widely utilized in over-the-counter formulations, making them easily accessible to consumers. The simplicity of these medications and their effectiveness in alleviating acid-related discomfort contribute significantly to their sustained popularity. As consumer awareness regarding the management of acid reflux increases, the demand for antacid-based products is expected to remain strong in the market.

H2 Receptor Antagonists:

The ingredient type of H2 receptor antagonists plays a vital role in the gastrointestinal drugs market, offering targeted solutions for reducing gastric acid secretion. Active ingredients such as ranitidine and famotidine are commonly used in these medications, providing effective treatment options for conditions like GERD and peptic ulcers. As healthcare providers increasingly recognize the importance of targeted therapies, the demand for H2 receptor antagonists remains robust. The ongoing development of new formulations with improved efficacy and side-effect profiles will likely continue to position this ingredient type favorably within the market.

Prokinetics:

Prokinetic agents, known for their ability to enhance gastrointestinal motility, are becoming increasingly important in the gastrointestinal drugs market. These medications, which include active ingredients such as metoclopramide, are crucial for treating conditions like gastroparesis and functional dyspepsia. As awareness of motility issues grows, the demand for prokinetic drugs is expected to rise. The development of novel prokinetic agents with improved mechanisms of action and fewer side effects has the potential to attract more patients seeking relief from gastrointestinal discomfort, further boosting the market's growth.

Probiotics:

Probiotics are an emerging ingredient type within the gastrointestinal drugs market, gaining recognition for their role in promoting gut health and balancing the microbiome. As consumers increasingly seek natural approaches to health and wellness, the demand for probiotic-based supplements and medications has surged. Probiotics are particularly beneficial for managing conditions like diarrhea and irritable bowel syndrome, helping to restore gut flora. The growing body of research supporting the efficacy of probiotics in promoting gastrointestinal health is likely to drive their integration into pharmaceutical products, expanding their presence in the market.

Laxatives:

Laxatives are essential in the gastrointestinal drugs market, providing relief for individuals experiencing constipation. This ingredient type encompasses various formulations, including osmotic, stimulant, and bulk-forming laxatives, catering to different patient needs. The increasing prevalence of constipation, particularly among the aging population and those with sedentary lifestyles, has driven demand for laxative products. Moreover, the emphasis on digestive health and the desire for effective over-the-counter solutions further enhance the market potential for laxatives. As innovative formulations with improved safety profiles are developed, the segment is expected to experience sustained growth.

By Region

The regional analysis of the gastrointestinal drugs market reveals significant growth potential across various geographies. North America dominates the market, accounting for approximately 40% of the global share, driven by high healthcare spending, advanced medical infrastructure, and a growing awareness of gastrointestinal disorders. The region's aging population also contributes to an increased prevalence of gastrointestinal diseases, further amplifying the demand for relevant medications. Moreover, the presence of key pharmaceutical companies and ongoing research initiatives bolster the region's market position, with a projected CAGR of 5.2% from 2025 to 2035, reflecting sustained growth.

Europe holds the second-largest market share, comprising around 30% of the global gastrointestinal drugs market. The region benefits from a robust healthcare system and increasing investments in pharmaceutical research and development. The rising prevalence of conditions such as IBD and GERD, coupled with an expanding aging population, is likely to propel demand for gastrointestinal medications. Additionally, developing economies within Europe are contributing to market growth, as healthcare access improves and awareness of gastrointestinal health issues rises, leading to a projected CAGR of 5.5% in the coming years. Meanwhile, Asia Pacific, Latin America, and the Middle East & Africa regions represent emerging markets with promising growth, driven by increasing healthcare access and rising awareness of gastrointestinal disorders.

Opportunities

The gastrointestinal drugs market presents numerous opportunities for growth and innovation. One significant opportunity lies in the ongoing research and development of personalized medicine for gastrointestinal disorders. As understanding of the microbiome and its impact on gastrointestinal health continues to evolve, pharmaceutical companies are well-positioned to develop targeted therapies that cater to individual needs. This approach not only enhances treatment efficacy but also fosters patient adherence to therapeutic regimens. Furthermore, the growing trend of preventive healthcare encourages patients to seek medications that support gastrointestinal wellness, creating a lucrative market for preventive therapies. The integration of digital health technologies, including telemedicine and mobile health applications, presents additional opportunities for companies to enhance patient engagement and streamline medication access.

Additionally, emerging markets in regions such as Asia Pacific and Latin America offer a wealth of opportunities for expansion. The increasing healthcare expenditure and improving access to medications in these areas provide a favorable environment for pharmaceutical companies looking to enter or expand their presence in these markets. The rising prevalence of gastrointestinal disorders, driven by changing lifestyles and dietary habits among the growing population, further amplifies the potential for growth. Companies may also capitalize on the demand for natural and herbal gastrointestinal remedies, aligning with consumer preferences for holistic health solutions. Overall, the gastrointestinal drugs market is poised for significant growth, bolstered by innovation, consumer awareness, and evolving healthcare landscapes.

Threats

While the gastrointestinal drugs market presents substantial growth opportunities, it is not without its threats. One of the most pressing threats is the increasing regulatory scrutiny and stringent approval processes for new medications. Pharmaceutical companies must navigate complex regulatory landscapes, which can lead to delays in bringing innovative products to market. Furthermore, the risk of product recalls due to safety concerns or adverse effects can damage a company's reputation and impact financial performance. The competitive landscape is also intensifying, with numerous players vying for market share, which can lead to price wars and reduced profit margins. Additionally, the rising trend of self-medication may lead to misuse of gastrointestinal drugs, resulting in adverse health outcomes and potential backlash against certain medications.

Another notable threat is the growing prevalence of counterfeit medications and unregulated online pharmacies, which undermine the integrity of the market and pose significant risks to consumer safety. The emergence of alternative therapies, such as dietary supplements and herbal remedies, also poses a challenge to traditional pharmaceutical companies in maintaining market share. As consumers increasingly seek holistic and natural approaches to health, companies must adapt and innovate to meet changing preferences. Finally, economic downturns and fluctuations in healthcare budgets may impact spending on gastrointestinal drugs, presenting additional challenges for market participants striving to sustain growth and profitability.

Competitor Outlook

• Pfizer Inc.
• GlaxoSmithKline plc
• Johnson & Johnson
• AbbVie Inc.
• Boehringer Ingelheim GmbH
• AstraZeneca plc
• Takeda Pharmaceutical Company Limited
• Sanofi S.A.
• Bristol Myers Squibb Company
• Merck & Co., Inc.
• Amgen Inc.
• Roche Holding AG
• Celgene Corporation
• Teva Pharmaceutical Industries Limited
• Gilead Sciences, Inc.

The competitive landscape of the gastrointestinal drugs market is characterized by a diverse range of players, including established multinational companies, generic drug manufacturers, and emerging biotech firms. Leading pharmaceutical companies, such as Pfizer Inc., GlaxoSmithKline, and Johnson & Johnson, dominate the market, leveraging their extensive product portfolios, significant R&D investments, and strong distribution networks. These companies are continuously innovating to develop novel therapies, enhancing treatment efficacy, and addressing unmet medical needs within the gastrointestinal space. Additionally, strategic partnerships and collaborations among these companies have become increasingly common, enabling them to share resources and expertise in the development of advanced gastrointestinal medications.

Generic drug manufacturers also play a critical role in the gastrointestinal drugs market, offering cost-effective alternatives to branded medications. Companies like Teva Pharmaceutical Industries and Mylan N.V. focus on producing generic formulations of popular gastrointestinal drugs, thereby contributing to market accessibility and affordability. The presence of these generics often leads to price competition, which can exert downward pressure on margins for branded pharmaceutical companies. However, renowned companies are countering this trend by differentiating their products through value-added features, such as extended-release formulations and combination therapies, which help maintain a competitive edge.

Emerging biotech firms are also making strides in the gastrointestinal drugs market, focusing on innovative treatments and novel therapeutic approaches. These companies often concentrate on specific niches within the market, such as probiotics or personalized medicine for gastrointestinal disorders, allowing them to carve out unique positions. Collaborations with academic institutions and research organizations enable these firms to accelerate product development and contribute new insights into gastrointestinal health. The dynamic nature of the competitive landscape necessitates that all players remain agile and adaptive, leveraging technological advancements and consumer trends to achieve sustained growth and success.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Amgen Inc.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 AbbVie Inc.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Pfizer Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Sanofi S.A.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 AstraZeneca plc
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Roche Holding AG
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Johnson & Johnson
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Merck & Co., Inc.
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Celgene Corporation
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 GlaxoSmithKline plc
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Gilead Sciences, Inc.
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Boehringer Ingelheim GmbH
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Bristol Myers Squibb Company
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Takeda Pharmaceutical Company Limited
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Teva Pharmaceutical Industries Limited
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Gastrointestinal Drugs Market, By Application
    • 6.1.1 Acid-related Diseases
    • 6.1.2 Inflammatory Bowel Disease
    • 6.1.3 Irritable Bowel Syndrome
    • 6.1.4 Constipation
    • 6.1.5 Others
  • 6.2 Gastrointestinal Drugs Market, By Product Type
    • 6.2.1 Antacids
    • 6.2.2 Proton Pump Inhibitors
    • 6.2.3 H2 Receptor Antagonists
    • 6.2.4 Prokinetics
    • 6.2.5 Antiemetics
  • 6.3 Gastrointestinal Drugs Market, By Ingredient Type
    • 6.3.1 Antacids
    • 6.3.2 H2 Receptor Antagonists
    • 6.3.3 Prokinetics
    • 6.3.4 Probiotics
    • 6.3.5 Laxatives
  • 6.4 Gastrointestinal Drugs Market, By Distribution Channel
    • 6.4.1 Hospital Pharmacies
    • 6.4.2 Retail Pharmacies
    • 6.4.3 Online Pharmacies

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Gastrointestinal Drugs Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Gastrointestinal Drugs market is categorized based on

By Product Type

• Antacids
• Proton Pump Inhibitors
• H2 Receptor Antagonists
• Prokinetics
• Antiemetics

By Application

• Acid-related Diseases
• Inflammatory Bowel Disease
• Irritable Bowel Syndrome
• Constipation
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Ingredient Type

• Antacids
• H2 Receptor Antagonists
• Prokinetics
• Probiotics
• Laxatives

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Pfizer Inc.
• GlaxoSmithKline plc
• Johnson & Johnson
• AbbVie Inc.
• Boehringer Ingelheim GmbH
• AstraZeneca plc
• Takeda Pharmaceutical Company Limited
• Sanofi S.A.
• Bristol Myers Squibb Company
• Merck & Co., Inc.
• Amgen Inc.
• Roche Holding AG
• Celgene Corporation
• Teva Pharmaceutical Industries Limited
• Gilead Sciences, Inc.